These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35840658)

  • 1. Formyl peptide receptor 2 as a potential therapeutic target for inflammatory bowel disease.
    Yang WS; Wang JL; Wu W; Wang GF; Yan J; Liu Q; Wu XY; Zhou QT; Yang DH; Wang MW; Li ZP
    Acta Pharmacol Sin; 2023 Jan; 44(1):19-31. PubMed ID: 35840658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the design and development of formyl peptide receptor 2 (FPR2/ALX) agonists as pro-resolving agents with diverse therapeutic potential.
    Maciuszek M; Cacace A; Brennan E; Godson C; Chapman TM
    Eur J Med Chem; 2021 Mar; 213():113167. PubMed ID: 33486199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating neutrophilic inflammation in COPD by targeting ALX/FPR2 resolution pathways.
    Bozinovski S; Anthony D; Anderson GP; Irving LB; Levy BD; Vlahos R
    Pharmacol Ther; 2013 Dec; 140(3):280-9. PubMed ID: 23880288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of resolution sensor drives age-related cardiometabolic and cardiorenal defects and impedes inflammation-resolution in heart failure.
    Tourki B; Kain V; Pullen AB; Norris PC; Patel N; Arora P; Leroy X; Serhan CN; Halade GV
    Mol Metab; 2020 Jan; 31():138-149. PubMed ID: 31918915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation.
    Motwani MP; Colas RA; George MJ; Flint JD; Dalli J; Richard-Loendt A; De Maeyer RP; Serhan CN; Gilroy DW
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALX/FPR2 Activation by Stereoisomers of D1 Resolvins Elucidating with Molecular Dynamics Simulation.
    Nunes VS; Abrahão O; Rogério AP; Serhan CN
    J Phys Chem B; 2023 Jul; 127(29):6479-6486. PubMed ID: 37428488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FPR2/ALXR agonists and the resolution of inflammation.
    Corminboeuf O; Leroy X
    J Med Chem; 2015 Jan; 58(2):537-59. PubMed ID: 25365541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electroacupuncture decreases inflammatory pain through a pro-resolving mechanism involving the peripheral annexin A1-formyl peptide receptor 2/ALX-opioid receptor pathway.
    Vieira C; Salm DC; Horewicz VV; Ludtke DD; Emer AA; Koerich JF; Mazzardo G; Elias S; Moré AOO; Mazzardo-Martins L; Cidral-Filho FJ; Reed WR; Piovezan AP; Martins DF
    Pflugers Arch; 2021 Apr; 473(4):683-695. PubMed ID: 33474635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cells mediate early neutrophil recruitment and exhibit anti-inflammatory properties via the formyl peptide receptor 2/lipoxin A
    Hughes EL; Becker F; Flower RJ; Buckingham JC; Gavins FNE
    Br J Pharmacol; 2017 Jul; 174(14):2393-2408. PubMed ID: 28471519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formyl peptide receptor 2, as an important target for ligands triggering the inflammatory response regulation: a link to brain pathology.
    Tylek K; Trojan E; Regulska M; Lacivita E; Leopoldo M; Basta-Kaim A
    Pharmacol Rep; 2021 Aug; 73(4):1004-1019. PubMed ID: 34105114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of the FPR2/ALX agonist AT-01-KG in the resolution of articular inflammation.
    Galvão I; Melo EM; de Oliveira VLS; Vago JP; Queiroz-Junior C; de Gaetano M; Brennan E; Gahan K; Guiry PJ; Godson C; Teixeira MM
    Pharmacol Res; 2021 Mar; 165():105445. PubMed ID: 33493655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature.
    Brancaleone V; Dalli J; Bena S; Flower RJ; Cirino G; Perretti M
    J Immunol; 2011 Apr; 186(8):4905-14. PubMed ID: 21398608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into the Activation Mechanism of the ALX/FPR2 Receptor.
    Schmitz Nunes V; Rogério AP; Abrahão O
    J Phys Chem Lett; 2020 Nov; 11(21):8952-8957. PubMed ID: 33030905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic regulation of the formyl peptide receptor 2 gene.
    Simiele F; Recchiuti A; Patruno S; Plebani R; Pierdomenico AM; Codagnone M; Romano M
    Biochim Biophys Acta; 2016 Oct; 1859(10):1252-8. PubMed ID: 27424221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of Formyl Peptide Receptor 2 for
    Boltersdorf T; Ansari J; Senchenkova EY; Groeper J; Pajonczyk D; Vital SA; Kaur G; Alexander JS; Vogl T; Rescher U; Long NJ; Gavins FNE
    Theranostics; 2020; 10(15):6599-6614. PubMed ID: 32550892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specialized Proresolving Lipid Meditators Agonistic to Formyl Peptide Receptor Type 2 Attenuate Ischemia-reperfusion Injury in Rat Lung.
    Oda H; Tanaka S; Shinohara M; Morimura Y; Yokoyama Y; Kayawake H; Yamada Y; Yutaka Y; Ohsumi A; Nakajima D; Hamaji M; Menju T; Date H
    Transplantation; 2022 Jun; 106(6):1159-1169. PubMed ID: 34873128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of the FPR2/ALX receptor in atherosclerosis development and plaque stability.
    Petri MH; Laguna-Fernández A; Gonzalez-Diez M; Paulsson-Berne G; Hansson GK; Bäck M
    Cardiovasc Res; 2015 Jan; 105(1):65-74. PubMed ID: 25341894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
    Stalder AK; Lott D; Strasser DS; Cruz HG; Krause A; Groenen PM; Dingemanse J
    Br J Clin Pharmacol; 2017 Mar; 83(3):476-486. PubMed ID: 27730665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Lipidated Peptidomimetic Lau-((S)-Aoc)-(Lys-βNphe)6-NH2 Is a Novel Formyl Peptide Receptor 2 Agonist That Activates Both Human and Mouse Neutrophil NADPH Oxidase.
    Holdfeldt A; Skovbakke SL; Winther M; Gabl M; Nielsen C; Perez-Gassol I; Larsen CJ; Wang JM; Karlsson A; Dahlgren C; Forsman H; Franzyk H
    J Biol Chem; 2016 Sep; 291(38):19888-99. PubMed ID: 27422818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of FPR2 impaired leukocytes recruitment and elicited non-resolving inflammation in acute heart failure.
    Kain V; Jadapalli JK; Tourki B; Halade GV
    Pharmacol Res; 2019 Aug; 146():104295. PubMed ID: 31216426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.